Business Wire - August 13, 2004
The publication is an authoritative review of the development of cannabis-based medicines and their applications in a wide range of therapeutic areas. It has been edited by Dr Geoffrey W Guy (Executive Chairman, GW Pharmaceuticals), Dr Philip J Robson (Senior Research Fellow, Department of Psychiatry, Oxford University and Medical Director, GW Pharmaceuticals) and Dr Brian A Whittle (Scientific Director, GW Pharmaceuticals).
The publication focuses on the research, development and clinical trial results of the cannabis-based medicinal extract (CBME) Sativex for the relief of chronic pain in MS sufferers, currently under review by the MHRA for registration. It also covers a broad spectrum of subjects including the history of cannabis use, its growth and morphology, the discovery and pharmacology of cannabinoid receptors in mammalian tissues, the development and use of synthetic cannabinoids, and the legal and forensic aspects of cannabis within the international community.
Further chapters explore the research into the basic science of cannabis and cannabinoids and highlight promising applications of CBMEs in the treatment of epilepsy, schizophrenia, bladder dysfunction and as broad-spectrum relief agents in patients with AIDS or cancer.
Professor Tony Moffat, the Society's Chief Scientist, said: "This publication demonstrates the scientific credentials of cannabis and cannabinoids as medicines. It is hoped that the evidence presented will help to change the attitude of health professionals towards cannabis-based medicines and enable the international legislative change required to allow further collaborative research into prescription medicines."
For further information and bulk sales opportunities, please contact 847-543-1708, pharmpress@ameritech.net or visit www.pharmpress.com. For orders, please contact 800-538-1287. The cost of the publication is $59.95.
CONTACT: Pharmaceutical Press
Kevin Tuley, 847-543-1708
North American Marketing & Sales Manager
kevin_tuley@ameritech.net
or
Doug Purington, 847-543-1708
Office Coordinator
pharmpress@ameritech.net
SOURCE: Pharmaceutical Press
040813
BW040810
Copyright © 2004 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .